Faruqi & Faruqi Investigates Regencell Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RGC?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited, focusing on investor losses incurred between October 28, 2024, and October 31, 2025, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors who purchased Regencell securities during this period to contact them before the June 23, 2026 deadline to seek lead plaintiff status, emphasizing the importance of timely action.
- Securities Class Action: A federal securities class action has been filed against Regencell, which may negatively impact the company's reputation and stock price, prompting investors to monitor further developments closely.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has provided direct contact information, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to client support.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Regencell Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited, focusing on investor losses incurred between October 28, 2024, and October 31, 2025, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors who purchased Regencell securities during this period to contact them before the June 23, 2026 deadline to seek lead plaintiff status, emphasizing the importance of timely action.
- Securities Class Action: A federal securities class action has been filed against Regencell, which may negatively impact the company's reputation and stock price, prompting investors to monitor further developments closely.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has provided direct contact information, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to client support.
See More
Regencell Bioscience Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC), encouraging those who purchased shares during the class period from October 28, 2024, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Overview: The complaint alleges that during the class period, Regencell made materially false and/or misleading statements and failed to disclose its vulnerability to market manipulation, exposing investors to substantial financial risks that could harm the company's reputation and legal standing.
- Registration Deadline: Shareholders must register by June 23, 2026, to participate in the class action, and failure to register in time may affect their rights to claims, highlighting the urgency of the legal matters facing the company.
- Rights Protection Participation: Once registered, shareholders will be enrolled in a portfolio monitoring software to receive real-time updates on the case's progress, ensuring that investor rights are safeguarded throughout the legal process, reflecting a commitment to protecting investor interests.
See More
Class Action Lawsuit Announced for Regencell Bioscience Holdings
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Regencell Bioscience Holdings (NASDAQ: RGC) for securities purchasers between October 28, 2024, and October 31, 2025, indicating potential financial risks for investors.
- Compensation Structure: Investors joining the class action may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which alleviates financial burdens and encourages more victims to participate.
- Counsel Selection Importance: The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record, highlighting its achievement of the largest securities class action settlement against a Chinese company in 2017, thereby enhancing its credibility among investors.
- Market Risk Disclosure: The lawsuit alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and legal repercussions, reflecting potential crises in regulatory and legal aspects for the company.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited (NASDAQ:RGC) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 28, 2024, and October 31, 2025.
- Market Manipulation Risks: The complaint alleges that Regencell made false and misleading statements, leading to significant stock volatility due to market manipulation, which exposed the company to regulatory scrutiny and reputational harm.
- Investor Losses: As the market learned the truth about Regencell, investors suffered damages, prompting the Schall Law Firm to encourage affected investors to contact them before June 23, 2026, to participate in the lawsuit and seek recovery.
- Legal Consultation Opportunity: The class has not yet been certified, meaning investors are not represented by an attorney during this period; the Schall Law Firm offers free consultations to ensure investors understand their rights and take appropriate action.
See More
Regencell Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of securities laws, involving trades from October 28, 2024, to October 31, 2025, potentially impacting investor rights.
- Market Manipulation Risk: The complaint alleges that Regencell made false and misleading public statements during this period, leading to significant stock volatility due to market manipulation, which increased the risk of regulatory scrutiny and reputational harm.
- Investor Losses: Following the revelation of the truth about Regencell, investors suffered damages, and the Schall Law Firm encourages affected shareholders to contact them before June 23, 2026, to participate in the lawsuit and seek compensation for their losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or website to understand their rights and potential legal actions they can take.
See More
Class Action Lawsuit Announced for Regencell Bioscience Holdings
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected investors to participate, thereby amplifying the lawsuit's impact.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation and the financial risks posed to investors during the class period, potentially leading to increased regulatory scrutiny that could adversely affect the company's market performance.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and credibility in handling similar cases.
See More
Faruqi & Faruqi Investigates Regencell Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited, focusing on investor losses incurred between October 28, 2024, and October 31, 2025, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors who purchased Regencell securities during this period to contact them before the June 23, 2026 deadline to seek lead plaintiff status, emphasizing the importance of timely action.
- Securities Class Action: A federal securities class action has been filed against Regencell, which may negatively impact the company's reputation and stock price, prompting investors to monitor further developments closely.
- Contact Information Provided: Securities Litigation Partner Josh Wilson has provided direct contact information, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to client support.
See More
Regencell Bioscience Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC), encouraging those who purchased shares during the class period from October 28, 2024, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Overview: The complaint alleges that during the class period, Regencell made materially false and/or misleading statements and failed to disclose its vulnerability to market manipulation, exposing investors to substantial financial risks that could harm the company's reputation and legal standing.
- Registration Deadline: Shareholders must register by June 23, 2026, to participate in the class action, and failure to register in time may affect their rights to claims, highlighting the urgency of the legal matters facing the company.
- Rights Protection Participation: Once registered, shareholders will be enrolled in a portfolio monitoring software to receive real-time updates on the case's progress, ensuring that investor rights are safeguarded throughout the legal process, reflecting a commitment to protecting investor interests.
See More
Class Action Lawsuit Announced for Regencell Bioscience Holdings
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Regencell Bioscience Holdings (NASDAQ: RGC) for securities purchasers between October 28, 2024, and October 31, 2025, indicating potential financial risks for investors.
- Compensation Structure: Investors joining the class action may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which alleviates financial burdens and encourages more victims to participate.
- Counsel Selection Importance: The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record, highlighting its achievement of the largest securities class action settlement against a Chinese company in 2017, thereby enhancing its credibility among investors.
- Market Risk Disclosure: The lawsuit alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and legal repercussions, reflecting potential crises in regulatory and legal aspects for the company.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited (NASDAQ:RGC) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 28, 2024, and October 31, 2025.
- Market Manipulation Risks: The complaint alleges that Regencell made false and misleading statements, leading to significant stock volatility due to market manipulation, which exposed the company to regulatory scrutiny and reputational harm.
- Investor Losses: As the market learned the truth about Regencell, investors suffered damages, prompting the Schall Law Firm to encourage affected investors to contact them before June 23, 2026, to participate in the lawsuit and seek recovery.
- Legal Consultation Opportunity: The class has not yet been certified, meaning investors are not represented by an attorney during this period; the Schall Law Firm offers free consultations to ensure investors understand their rights and take appropriate action.
See More
Regencell Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of securities laws, involving trades from October 28, 2024, to October 31, 2025, potentially impacting investor rights.
- Market Manipulation Risk: The complaint alleges that Regencell made false and misleading public statements during this period, leading to significant stock volatility due to market manipulation, which increased the risk of regulatory scrutiny and reputational harm.
- Investor Losses: Following the revelation of the truth about Regencell, investors suffered damages, and the Schall Law Firm encourages affected shareholders to contact them before June 23, 2026, to participate in the lawsuit and seek compensation for their losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or website to understand their rights and potential legal actions they can take.
See More
Class Action Lawsuit Announced for Regencell Bioscience Holdings
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected investors to participate, thereby amplifying the lawsuit's impact.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation and the financial risks posed to investors during the class period, potentially leading to increased regulatory scrutiny that could adversely affect the company's market performance.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and credibility in handling similar cases.
See More
